Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHEPHERD: SUL-238 in Early, Untreated Parkinson's Disease
NCT07322887Phase 2Recruiting
- Sponsor
- Gen Ilac Ve Saglik Urunleri
- Start
- May 2026
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SUL-238 in Parkinson's disease (PD), sponsored by Gen Ilac Ve Saglik Urunleri. Started May 2026; status: recruiting.
02
Drugs
SUL-238
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT07322887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07322887.